Link: http://mobile.reuters.com/article/idUSL1N12L1SB20151022

——————–

in the Valeant Pharmaceuticals stock price meltdown . . . and the controversies around Valeant.

“Hedge fund managers with great track records have stood by their conviction that Valeant is a great company despite a growing list of questions about its business model, its pricing policies, its pile of debt and the determination of potential acquisition targets to stay out of Valeant’s clutches,” said Erik Gordon, a professor at the University of Michigan’s law and business schools.

Reuters:

http://mobile.reuters.com/article/idUSL1N12L1SB20151022

CNBC:

http://www.cnbc.com/2015/10/21/reuters-america-update-2-valeant-meltdown-costs-investors-billions-ackman-ups-stake.html

Erik Gordon
Ross School of Business
University of Michigan